European Union - English - EMA (European Medicines Agency)

krka, d.d., novo mesto - repaglinide - diabetes mellitus, type 2 - drugs used in diabetes - repaglinide is indicated in patients with type-2 diabetes (non-insulin-dependent diabetes mellitus (niddm)) whose hyperglycaemia can no longer be controlled satisfactorily by diet, weight reduction and exercise. repaglinide is also indicated in combination with metformin in type-2 diabetes patients who are not satisfactorily controlled on metformin alone.treatment should be initiated as an adjunct to diet and exercise to lower the blood glucose in relation to meals.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

consilient health ltd - repaglinide - tablet - 500microgram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

consilient health ltd - repaglinide - tablet - 1mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

consilient health ltd - repaglinide - tablet - 2mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

plantago lanceolata) pollen 50,000sbu/ml solution for skin prick test (allergopharma - english plantain (plantago lanceolata) pollen allergen extract - solution for skin-prick test

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

plantago lanceolata) pollen 50hep/ml solution for skin prick test (inmunotek - english plantain (plantago lanceolata) pollen allergen extract - solution for skin-prick test

Australia - English - Department of Health (Therapeutic Goods Administration)

device technologies australia pty ltd - 18074 - eyelid weight, implantable - a weighted device implanted within the upper eyelid/palpebral to restore upper eyelid function.